The powerful intelligence alert function of the Patsnap Synapse database makes it easy for you to complete various monitoring tasks.

U.S. authorities expedite assessment of ENHERTU® for individuals suffering from advanced solid cancers with HER2-positive status.

Methylprednisolone is a perplexing small molecule drug that targets both the NMDA receptor as a modulator and the glucocorticoid receptor as an agonist.

Nivolumab plus hyaluronidase administered beneath the skin is comparably effective to Opdivo given intravenously for advanced or metastatic clear cell kidney cancer as suggested by study CheckMate -67T.

Propranolol Hydrochloride, a small molecule drug, targets the β-adrenoceptors as an antagonist, exhibiting an assortment of therapeutic effects.

On Jan 26, Pfizer and Astellas Pharma announced that the European Medicines Agency (EMA) has accepted to review a Type II variation application for the combined use of PADCEV® and KEYTRUDA®.

Hydrochlorothiazide, a small molecule drug, targets the NCC co-transporter as an inhibitor, exhibiting an assortment of therapeutic effects.

KEYTRUDA® (Pembrolizumab) Enhances Disease-Free Survival (DFS) as Adjuvant in High-Risk Urothelial Carcinoma Post-Surgery.

Tizanidine Hydrochloride, a minuscule molecule drug, is a potent agonist that targets the ADRA2 receptor with high specificity.

Dupixent® has been granted FDA approval as the exclusive therapy indicated for pediatric patients over the age of 1 diagnosed with eosinophilic esophagitis (EoE).

Bupropion Hydrochloride is a tiny molecule drug that targets multiple functions, including dopamine transporter (DAT), adrenergic receptor, and CYP2D6.

Orion Presents New Insights from Phase II CYPIDES Trial on ODM-208 at 2024 ASCO Symposium.